ArticleEClinicalMedicine2026

REGENECYTE cord blood cell therapy in post-COVID syndrome: a phase IIa randomized, placebo-controlled trial.

Yen-Wen Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.